{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 42,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/30",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.63,
        "x": 0.186,
        "y": 0.33
      },
      "kind": "list",
      "text": "Successful EOP2 FDA meeting completed in October 2023; agreement that a 3-step change on the binocular person scale is an approvable registration endpoint\nSubmit Special Protocol Assessment (SPA)\nAdvance APX3330 into Phase 3 program with long-term exposure (up to 2 years)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49f4693a-e88f-4577-bae4-665984fcfa9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.066,
        "w": 0.104,
        "x": 0.073,
        "y": 0.701
      },
      "kind": "other",
      "text": "Our Goal for Patients",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22417478-9954-4b30-bef8-793323a4486b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.024,
        "w": 0.263,
        "x": 0.415,
        "y": 0.239
      },
      "kind": "other",
      "text": "APX3330 Milestones",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6799f989-8355-4053-a181-2deeec37fcb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.72,
        "x": 0.204,
        "y": 0.699
      },
      "kind": "paragraph",
      "text": "To have a clinically meaningful impact on slowing or preventing progression to reduce likelihood of vision loss in diabetic retinopathy patients",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "708c7e95-c50a-41ee-ba15-c40e3e7f4d92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.34,
        "x": 0.047,
        "y": 0.06
      },
      "kind": "title",
      "text": "APX3330 Summary",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d52c8743-66b1-48ef-b700-c5c7f56806e0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "bda61679-4f3d-4bab-b7c0-dad6523092d7",
      "evidence": "list/bullet: Successful EOP2 FDA meeting completed in October 2023; agreement that a 3-step change on the binocular person scale is an approvable registration endpoint",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 29,
      "beatId": "691510f1-c63c-46db-bda1-6d94434f6f9b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 29-42 discuss key takeaways, corporate highlights, and future plans",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 30,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "73d97d04-557b-44ca-a1d1-9e0d6b27f716",
      "evidence": "Slides 30-31 summarize APX3330's benefits and key takeaways",
      "position": 1,
      "objective": "Why APX3330 is a good solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}